Back, Abdomen and Buttocks: Position the Pod horizontally or at a slight angle. Greg Nickleski isn't the biggest fan of needles and pricks -- so he discusses why he uses the new, slimmer OmniPod insulin pump. How to Select an Infusion Site on Your Body - Omnipod® System … Secure the device your health depends upon to prevent premature loosening and loss of pods during even the most intense activities. Details . You will be able to edit the text before publishing. Please SUBSCRIBE we upload every Monday, Wednesday & Fridays! Choosing to participate in a study is an important personal decision. Poor customer service. Omnipod 155. Review #1667938 . Although as an OmniPod user, I can see my pod through my clothes, pretty much everyone else won’t notice it. Arm band to help hold and protect your diabetic sensors, Omnipod, Dexcom, Libre. can you recommend the arm? Comfortable, discreet protection! Pregnant or lactating, or is a woman of childbearing potential and not on acceptable form of birth control (acceptable includes abstinence, condoms, oral/injectable contraceptives, IUD, or implant), Participation in another clinical study using an investigational drug or device other than the Omnipod 5 in the preceding 30-days or intends to participate during the study period, Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the investigator's clinical judgment. Omnipod is wireless insulin pump that includes two parts: Remote control and Pod Remote control is simple to learn and use. 294 views . Contact Review Author as Verified Representative, Business Solutions For Verified Company Representatives, Pissed Consumer © 2021 All 2 weeks standard therapy - using multiple daily injections (MDI) and Dexcom G6 Continuous Glucose Monitor (CGM), followed by: 2 weeks standard therapy - using basal injection only and Dexcom G6 Continuous Glucose Monitor (CGM), followed by: 2 weeks Omnipod 5 system use in Manual Mode with Dexcom G6 Continuous Glucose Monitor (CGM) - with fixed basal rate, no bolus, followed by: Percent of time in range 70-180 mg/dL [ Time Frame: Automated Mode use (8-10 weeks) will be compared to the standard therapy phase (2 weeks) overall, separately for Group A and Group B ], Percent of time > 180 mg/dL [ Time Frame: Automated Mode use (8-10 weeks) will be compared to the standard therapy phase (2 weeks) overall, separately for Group A and Group B ], Percent of time ≥ 250 mg/dL [ Time Frame: Automated Mode use (8-10 weeks) will be compared to the standard therapy phase (2 weeks) overall, separately for Group A and Group B ], Percent of time ≥ 300 mg/dL [ Time Frame: Automated Mode use (8-10 weeks) will be compared to the standard therapy phase (2 weeks) overall, separately for Group A and Group B ], Percent of time < 70 mg/dL [ Time Frame: Automated Mode use (8-10 weeks) will be compared to the standard therapy phase (2 weeks) overall, separately for Group A and Group B ], Percent of time < 54 mg/dL [ Time Frame: Automated Mode use (8-10 weeks) will be compared to the standard therapy phase (2 weeks) overall, separately for Group A and Group B ], Standard Deviation [ Time Frame: Automated Mode use (8-10 weeks) will be compared to the standard therapy phase (2 weeks) overall, separately for Group A and Group B ], Coefficient of Variation [ Time Frame: Automated Mode use (8-10 weeks) will be compared to the standard therapy phase (2 weeks) overall, separately for Group A and Group B ], Mean glucose [ Time Frame: Automated Mode use (8-10 weeks) will be compared to the standard therapy phase (2 weeks) overall, separately for Group A and Group B ], Total daily Insulin (units) [ Time Frame: Automated Mode use (8-10 weeks) will be compared to the standard therapy phase (2 weeks) overall, separately for Group A and Group B ], Total daily insulin (units/kg) [ Time Frame: Automated Mode use (8-10 weeks) will be compared to the standard therapy phase (2 weeks) overall, separately for Group A and Group B ], Change in Hemoglobin A1c (HbA1c) [ Time Frame: End of study compared to baseline (Day 57 (Group A) or Day 71 (Group B) compared to Day -30 ], Diagnosed with type 2 diabetes on insulin therapy by injection: basal-bolus (12 subjects) or basal only (12 subjects) regimens, Has not used an insulin pump within 3 months of screening, Willing to use only the following types of insulin during the study: Humalog, Novolog, Admelog or Apidra during the study, Stable doses over the last 4 weeks of other glucose-lowering medications as determined by Investigator, Willing to wear the system continuously throughout the study, Deemed appropriate for pump therapy per investigator's assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities, Investigator has confidence that the subject has the cognitive ability and can successfully operate all study devices and can adhere to the protocol, Must be willing to use the Dexcom App on the Omnipod 5 PDM as the sole source of Dexcom data (except for the Dexcom Follow App) during Automated Mode, Subjects scoring ≥ 4 on the Clarke Questionnaire must agree to have an overnight companion, defined as someone who resides in the same home or building as the study subject and who can be available overnight, Willing and able to sign the Informed Consent Form (ICF), A medical condition, which in the opinion of the investigator, would put the subject at an unacceptable safety risk, History of severe hypoglycemia in the past 6 months, History of diabetic ketoacidosis (DKA) in the past 6 months, unrelated to an intercurrent illness, infusion set failure or initial diagnosis, Diagnosed with a blood dyscrasia or bleeding disorder, Plans to receive blood transfusion over the course of the study, Currently diagnosed with anorexia nervosa or bulimia, Has taken oral or injectable steroids within the past 8-weeks or plans to take oral or injectable steroids during the study, Unable to tolerate adhesive tape or has any unresolved skin condition in sensor or pump placement, Plans to use insulin other than U-100 insulin during the Omnipod 5 phase of the study.